This multi-site registry, centered at Duke University, will enroll pregnant women with autoimmune and rheumatologic diseases.
The main goal of MADRA is to identify ways to improve the health of women with rheumatic diseases and their babies during pregnancy.
Prior studies demonstrate the importance of increase inflammation prior to and during pregnancy on these outcomes. The future research will seek to better define these risk factors and to identify ways to may improve them.
Desire for pregnancy within 6 months or currently pregnant
Lupus (systemic lupus erythematosus or cutaneous lupus)
Antiphospholipid Syndrome or positive antiphospholipid antibodies
Rheumatoid Arthritis
Unable to speak English
Unable to provide informed consent
Unable to travel to Duke University for follow-up visits
Women who have been diagnosed with an autoimmune disease or a rheumatic condition.
Cohort
Prospective
Not listed
Risk factors associated with poor pregnancy outcomes as measured by the MADRA-DAP questionnaire.
The investigators will ask the participants questions from the MADRA-DAP questionnaire to determine poor pregnancy outcomes.
Click on the lead sponsor to view all of their trials.
